Lower middle market healthcare private equity firm
Albaron Partners
- HeadquartersNew York, NY S2
- Founded2017 S1
- Websitealbaronpartners.com
- Last verifiedOctober 27, 2026
At a glance
| Assets under management | $200M (as of October 2026) S1 |
|---|---|
| Latest fund | Albaron Healthcare Opportunities I, $185M (May 2026) S9 |
| EBITDA range | $1M to $10M S3 |
| Deal types | Platform, Add-on S4 |
| Geography | North America S3 |
| Sectors | Healthcare Services |
What Albaron Partners buys
Albaron Partners is a New York private equity firm, founded in 2017, that invests only in healthcare services. It looks for founder- or physician-owned companies in North America with $1 million to $10 million of EBITDA, a strong market position, a capable management team and steady demand. Beyond medical practices, it will look at businesses that serve providers and patients, such as equipment servicing, device rental, staffing, labs and logistics. In May 2026 it closed its first blind-pool fund, Albaron Healthcare Opportunities I, at its $185 million hard cap, and its website reports more than $200 million under management.
Founders and physicians keep significant equity alongside Albaron on the same terms, and physicians keep control of clinical decisions while the firm runs the business side. Albaron has made six platform investments, in vein care, podiatry, fertility, psychiatry, interventional radiology and home infusion, across 47 transactions in total. It grows each platform with add-on practices and also funds healthcare deals that independent sponsors bring to it.
Recent deals
Announced in the 24 months before October 27, 2026.
| Date | Company | Type | Sector | Source |
|---|---|---|---|---|
| Sep 2026 | Prime PsychiatryTexas outpatient and interventional psychiatry platform sold to Beacon Behavioral Partners | Exit | Healthcare Services | Source |
| May 2026 | Albaron Healthcare Opportunities IFirst blind-pool fund closed at its $185 million hard cap in under five months | Fund close | Source | |
| Jan 2026 | Vital Care infusion franchisee platformBought Vital Care of Dixie/Etown, Moorestown and Northfield; four infusion pharmacies with eight sites of care in four states | Platform | Healthcare Services | Source |
| Jan 2025 | IR MSOOffice-based interventional radiology platform formed with a leading physician | Platform | Healthcare Services | Source |
Portfolio by sector
From the firm's portfolio page S7.
Franchised Infusion Pharmacies
- Vital Care Infusion Services
Interventional Radiology
- IR MSO
Reproductive Medicine
- Innovation Fertility
Past investments: Prime Psychiatry, Beyond Podiatry, Metro Vein Centers
Greymont’s take
How Albaron Partners fits a seller
Albaron fits physicians and founders of healthcare services businesses who want to sell part of the company now and keep a real stake for a later, larger sale. Physicians are encouraged to roll a meaningful share of their proceeds and keep control of patient care, while Albaron takes on payers, recruiting, acquisitions and infrastructure. Its exits show what that second sale can look like: Beyond Podiatry went to CUC in 2024 at an $87 million valuation, and Prime Psychiatry went to Beacon Behavioral Partners in 2026. Practices too small to anchor a platform may fit as add-ons, as the three Vital Care pharmacies did in January 2026. Owners should ask how much of the proceeds Albaron expects them to roll over and how long it usually holds a platform before selling.
Questions owners ask
What size companies does Albaron invest in?
Its criteria call for North American healthcare and healthcare services companies with $1 million to $10 million of EBITDA. A January 2026 release gave the range as $2 million to $10 million.
Do physicians keep control of patient care?
Yes. Albaron says physicians keep full control over clinical and patient care decisions, hold significant equity on the same terms as the firm, and share in the value when the platform is sold.
Does Albaron work with independent sponsors?
Yes. It invites independent sponsors to bring healthcare services deals at any stage, funds them from its $185 million committed fund with no financing contingency, and says its deal terms reflect the sponsor's sourcing work.
Which companies has Albaron sold?
It reports three platform exits: Metro Vein Centers, held from 2017 to 2021; Beyond Podiatry, sold to CUC in 2024; and Prime Psychiatry, sold to Beacon Behavioral Partners in September 2026.
Sources
- S1Albaron Partners home page Accessed October 27, 2026
- S2Albaron Partners: The Firm Accessed October 27, 2026
- S3Albaron Partners: Our Approach and investment criteria Accessed October 27, 2026
- S4Albaron Partners: For Founders Accessed October 27, 2026
- S5Albaron Partners: For Physicians Accessed October 27, 2026
- S6Albaron Partners: For Independent Sponsors Accessed October 27, 2026
- S7Albaron Partners: Portfolio Accessed October 27, 2026
- S8Albaron Partners: News and Press Accessed October 27, 2026
- S9Albaron Partners Holds First and Final Close on $185 Million Fund (May 19, 2026) Accessed October 27, 2026
- S10Albaron Partners Completes Sale of Prime Psychiatry to Beacon Behavioral Partners (September 9, 2026) Accessed October 27, 2026
- S11Albaron Acquires Vital Care Infusion Franchisee Platform (January 12, 2026) Accessed October 27, 2026
- S12Albaron Forms IR MSO LLC (January 24, 2025) Accessed October 27, 2026
Compiled by Greymont Advisors from public sources, including the firm’s own website and press releases. Greymont is not affiliated with Albaron Partners. Figures are as reported on the dates shown and may have changed. Request a correction